Table 2.
Susceptibility rates (%) to cefepime/taniborbactam and comparators for GNB isolates, including highly resistant pathogens, from patients with cancer
| Species | No. tested isolates | No. susceptible isolates (% susceptibility) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| FTB | FEP | CZA | C/T | MEM | TZP | LVX | AMK | ||
| ESBL-producing E. coli | 20 | 20 (100) | 1 (5) | 20 (100) | 17 (85) | 20 (100) | 9 (45) | 2 (10) | 20 (100) |
| CRE E. coli | 10 | 8 (80) | 0 (0) | 5 (50) | 2 (20) | 3 (30) | 1 (10) | 0 (0) | 6 (60) |
| ESBL-producing K. pneumoniae | 25 | 25 (100) | 2 (8) | 25 (100) | 10 (40) | 25 (100) | 7 (28) | 8 (32) | 25 (100) |
| CRE K. pneumoniae | 20 | 20 (100) | 0 (0) | 16 (80) | 0 (0) | 3 (15) | 3 (15) | 0 (0) | 15 (75) |
| MDR P. aeruginosa | 20 | 19 (95) | 0 (0) | 14 (70) | 13 (65) | 2 (10) | 5 (25) | 0 (0) | 13 (65) |
| S. maltophilia | 30 | 30 (100) | 0 (0) | 10 (33.3) | 4 (13.3) | 0 (0) | 0 (0) | 17 (56.7) | 8 (26.7) |
| Total resistant isolates | 125 | 122 (97.6) | 3 (2.4) | 90 (72.0) | 46 (36.8) | 53 (42.4) | 25 (20.0) | 27 (21.6) | 87 (69.6) |
| Total non-resistant isolates | 145 | 145 (100.0) | 104 (71.7) | 143 (98.6) | 122 (84.1) | 136 (93.8) | 82 (56.6) | 111 (76.6) | 144 (99.3) |
| Total, all tested isolates | 270 | 267 (98.9) | 107 (39.6) | 233 (86.3) | 168 (62.2) | 191 (70.7) | 107 (39.6) | 138 (51.1) | 231 (85.6) |
FTB, cefepime/taniborbactam; FEP, cefepime; CZA, ceftazidime/avibactam; C/T, ceftolozane/tazobactam; MEM, meropenem; TZP, piperacillin/tazobactam; LVX, levofloxacin; AMK, amikacin.